Anti-VEGF therapy effectively manages myopic macular neovascularization (MNV) in the short term, but long-term data indicates that progressive retinal atrophy remains a significant risk. A recent study published in Graefe’s Archive of Clinical and Experimental Ophthalmology found that 59% of treated eyes developed atrophy within five years, identifying foveal involvement as the primary predictor of poor visual outcomes.
Why Does Atrophy Persist After Anti-VEGF Treatment?
Clinical data suggests that MNV-related atrophy is a degenerative, multifactorial process inherent to pathologic myopia rather than a direct side effect of anti-VEGF injections. According to the study of 39 treatment-naïve eyes, patients receiving ranibizumab or aflibercept saw significant improvements in best-corrected visual acuity (BCVA) and reductions in central retinal thickness. Despite these early therapeutic gains, the underlying progression of atrophy—categorized by researchers into perilesional, patchy, and post-hemorrhagic patterns—often leads to long-term vision loss.
How Do Atrophy Patterns Affect Visual Prognosis?
Researchers identified three distinct atrophic phenotypes that serve as markers for patient outcomes. Perilesional atrophy, the most common form, appeared more frequently in older patients. However, multivariate analysis revealed that foveal atrophy is the most significant determinant of poor BCVA. While baseline factors such as larger greatest linear dimension and subfoveal MNV were associated with atrophy, their impact diminished over time, leaving the location of the atrophy as the primary driver of visual decline.
Comparison of Atrophy Progression Types
| Atrophy Type | Prevalence |
|---|---|
| Perilesional | 74% |
| Patchy Expansion | 22% |
| Post-Hemorrhage | 4% |
What Should Clinicians Monitor for Long-Term Success?
Managing pathologic myopia requires looking beyond the initial resolution of the neovascular membrane. Because foveal atrophy remains the strongest indicator of poor vision, clinicians should focus on longitudinal imaging to detect early signs of tissue thinning. Early intervention with anti-VEGF agents remains the standard for stabilizing vision, but experts emphasize that providers must set expectations regarding the potential for progressive degenerative changes that occur independently of treatment frequency.
Frequently Asked Questions
- Does anti-VEGF treatment cause atrophy in myopic eyes? No. Researchers concluded that atrophy is likely a progressive, multifactorial feature of pathologic myopia rather than a treatment-induced phenomenon.
- Which atrophy pattern is most dangerous for vision? Foveal atrophy has been identified as the strongest determinant of poor long-term visual acuity.
- How common is atrophy after MNV treatment? In a five-year study of treatment-naïve eyes, 59% developed some form of MNV-related atrophy.
Are you tracking long-term outcomes in your myopic patients? Share your clinical observations in the comments below or subscribe to our newsletter for the latest updates in retinal research.
